/images/ppid_59c68470-image-176311002937591617.webp)
/images/ppid_59c68470-image-177083752855419301.webp)
/images/ppid_59c68470-image-177083752668871927.webp)
What is the story about?
Natco Pharma announced its September-quarter (Q2) earnings on Friday, November 14.
The company reported a 23.5% year-on-year decline in net profit, which came in at ₹518 crore compared with ₹677.3 crore in the same period last year.
Revenue for the quarter dipped slightly to ₹1,363 crore from ₹1,371 crore a year ago.
EBITDA also saw a sharp drop of 28%, falling to ₹579 crore versus ₹804 crore last year.
Consequently, the EBITDA margin narrowed to 42.5% from 58.6% year-on-year.
The board declared an interim dividend of ₹1.50 per equity share of face value ₹2 for the financial year 2025-26.
The record date for the dividend has been set as November 20, 2025, and payments will begin from November 28.
Shares of Natco Pharma Ltd. are trading 2% lower at ₹810. The stock has declined more than 40% so far in 2025.
The company reported a 23.5% year-on-year decline in net profit, which came in at ₹518 crore compared with ₹677.3 crore in the same period last year.
Revenue for the quarter dipped slightly to ₹1,363 crore from ₹1,371 crore a year ago.
EBITDA also saw a sharp drop of 28%, falling to ₹579 crore versus ₹804 crore last year.
Consequently, the EBITDA margin narrowed to 42.5% from 58.6% year-on-year.
The board declared an interim dividend of ₹1.50 per equity share of face value ₹2 for the financial year 2025-26.
The record date for the dividend has been set as November 20, 2025, and payments will begin from November 28.
Shares of Natco Pharma Ltd. are trading 2% lower at ₹810. The stock has declined more than 40% so far in 2025.
/images/ppid_a911dc6a-image-177084603066450478.webp)
/images/ppid_a911dc6a-image-177084257810510483.webp)
/images/ppid_a911dc6a-image-177084253417916956.webp)
/images/ppid_59c68470-image-177084004043125742.webp)
/images/ppid_a911dc6a-image-177083903258342419.webp)